Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Ferring Launches Novel Prostate Cancer Treatment Degarelix

  • News

Executive Summary

Swiss-drug maker Ferring launched its rapid onset prostate cancer treatment degarelix in the U.S. and Europe in March, marking the firm's first global launch

You may also be interested in...



Stelara And Firmagon Suffer Setbacks In Draft NICE Appraisals

Janssen has until Jan. 17 to argue the cost-effectiveness of Stelara in the additional indication, psoriatic arthritis, while Ferring faces a restricted indication recommendation for Firmagon.

Ferring Degarelix Prostate Cancer Drug To Launch In First Quarter

FDA approves the gonadotropin-releasing hormone receptor antagonist, which hasn’t shown the initial surge in testosterone seen with other therapies.

Ferring’s Degarelix Effectively Cut Testosterone Levels In Phase III Prostate Cancer Trial

However, more details are needed before clinicians get excited about this drug, one oncologist tells “The Pink Sheet” DAILY.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS050908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By